BIOGEN INC. Defined Contribution Plan, Cost
BIOGEN INC. (BIIB) reported Defined Contribution Plan, Cost of $39.30 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2014-02-06
- BIOGEN INC. defined contribution plan, cost for fiscal 2013 was $39.30M, a 19.82% increase from fiscal 2012.
- BIOGEN INC. defined contribution plan, cost for fiscal 2012 was $32.80M, a 32.26% increase from fiscal 2011.
- BIOGEN INC. defined contribution plan, cost for fiscal 2011 was $24.80M, a 5.70% decline from fiscal 2010.
- BIOGEN INC. defined contribution plan, cost for fiscal 2010 was $26.30M, a 5.73% decline from fiscal 2009.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2013-12-31 | $39.30M 10-K · filed 2014-02-06 |
| 2012-12-31 | $32.80M 10-K · filed 2014-02-06 |
| 2011-12-31 | $24.80M 10-K · filed 2014-02-06 |
| 2010-12-31 | $26.30M 10-K · filed 2013-02-05 |
| 2009-12-31 | $27.90M 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |